The clinical utility of comprehensive genomic profiling for recurrent / metastatic head and neck cancer

  • Tohyama Kohki
    Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University Department of Oral Radiation Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
  • Kano Yoshihito
    Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University Department of Clinical Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
  • Noji Rika
    Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
  • Aoyagi Yasuko
    Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University
  • Matsudera Shotaro
    Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University
  • Ohno Kazuchika
    Department of Head and Neck Surgery, Tokyo Medical and Dental University
  • Ariizumi Yosuke
    Department of Head and Neck Surgery, Tokyo Medical and Dental University
  • Michi Yasuyuki
    Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
  • Tomioka Hirofumi
    Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
  • Shimamoto Hiroaki
    Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
  • Yoshimura Ryoichi
    Department of Radiation Therapeutics and Oncology, Tokyo Medical and Dental University
  • Asakage Takahiro
    Department of Head and Neck Surgery, Tokyo Medical and Dental University
  • Harada Hiroyuki
    Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
  • Miyake Satoshi
    Department of Clinical Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
  • Miura Masahiko
    Department of Oral Radiation Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
  • Ikeda Sadakatsu
    Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University

Bibliographic Information

Other Title
  • 再発・転移頭頸部癌に対する網羅的がんゲノム解析と臨床的有用性

Search this article

Abstract

Background: Next-generation sequencing (NGS) of tumor samples in a clinical setting provides information regarding cancer-related genetic aberrations, and is therefore expected to be useful in precision medicine. However, the clinical utility of clinical sequencing remains unknown in solid cancers, including recurrent or metastatic head and neck cancer (R/M HNC) in Japan. Here, we conducted a hospital-based study to investigate the clinical utility of tumor-profiling gene panel testing in R/M HNC. <br>Methods: We examined 18 panel tests from 14 cases of R/M HNC; 15 underwent tumor tissue-based panel testing (FoundationOne CDx® and/or FoundationOne HEME®) and three underwent liquid biopsy (Guardant360®), with three cases undergoing both investigations. <br>Results: There were nine men and five women of median age 58 years (38-73 years). There were ten cases of squamous cell carcinoma (SCC) and four of non-SCC. The most common genetic alteration was inactivation of TP53 followed by TERT promoter and CDKN2A alterations. There was no suspected hereditary neoplastic syndrome. Gene profiling data was obtained for 11 cases (78.6%) that harbored at least one actionable gene aberration. Two cases (14.3%) had undergone molecular targeted therapy. The median value of the tumor mutational burden (TMB) was 6.0 Muts/Mb (0-34) and the disease control rate of the three cases with high TMB (≥10 Muts/Mb) was 66.7% (partial response: 2, progressive disease: 1) following treatment with an immune-checkpoint inhibitor such as nivolumab or pembrolizumab. <br>Conclusions: These results indicate the clinical utility of tumor-profiling multiplex gene panel testing in R/M HNC in Japan.

Journal

  • Toukeibu Gan

    Toukeibu Gan 47 (4), 359-365, 2021

    Japan Society for Head and Neck Cancer

References(11)*help

See more

Related Projects

See more

Details 詳細情報について

Report a problem

Back to top